| Literature DB >> 25957352 |
Abstract
UNLABELLED: Copy number abnormalities (CNAs) such as somatically-acquired chromosomal deletions and duplications drive the development of cancer. As individual tumor genomes can contain tens or even hundreds of large and/or focal CNAs, a major difficulty is differentiating between important, recurrent pathogenic changes and benign changes unrelated to the subject's phenotype. Here we present Copy Number Explorer, an interactive tool for mining large copy number datasets. Copy Number Explorer facilitates rapid visual and statistical identification of recurrent regions of gain or loss, identifies the genes most likely to drive CNA formation using the cghMCR method and identifies recurrently broken genes that may be disrupted or fused. The software also allows users to identify recurrent CNA regions that may be associated with differential survival.Entities:
Mesh:
Year: 2015 PMID: 25957352 PMCID: PMC4547619 DOI: 10.1093/bioinformatics/btv298
Source DB: PubMed Journal: Bioinformatics ISSN: 1367-4803 Impact factor: 6.937
Fig. 1.Copy Number Explorer Workflow. (A) Aberration frequency plot shows proportion of samples with gains and losses from GBM (n = 580). Chromosomes are placed in order along the x-axis and the proportion of gains (dark grey; positive numbers) or losses (light grey; negative numbers) are shown on the y-axis. (B) cghMCR-transformed data results in a segment gain or loss (SGOL) score on the y-axis. High absolute SGOL scores indicate one or a combination of highly focal, high frequency or a high magnitude of alterations across multiple samples: SGOL score can be used to identify the gene most likely to be the target of gain or loss. Genes with the highest SGOL scores for chromosomes 1, 4, 7, 9 and 12 are indicated. (C, D) Data is partitioned based on the presence of a gain or amplification of the EGFR locus (indicated by an asterisk). Group 1 (n = 499) (C) shows 100% of cases have this abnormality whereas no cases in Group 2 (n = 81) do (D). (E) Kaplan–Meier curve shows that subjects with an EGFR gain or amplification have a poorer prognosis than those without